FDA’s Center for Drug Evaluation and Research (CDER) is pleased to announce its partnership with the Critical Path Institute (C-Path) to explore the feasibility of launching the Lysosomal Diseases Consortium, a public-private partnership among FDA, leading academic institutions, pharmaceutical indus